Description

The global poc diagnostics market is poised to grow by US$ 22.0 billion from 2022 to 2028, registering a CAGR of 10.1% during the forecast period, according to StrategyHelix.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for poc diagnostics. The global poc diagnostics market is segmented on the basis of type, product, end user, and region. By type, the global poc diagnostics market has been segmented into alcohol and drug abuse, blood gas electrolyte and metabolite (BGEM), cardiac markers, cholesterol, glucose monitoring, hemoglobin/hemostasis, infectious diseases, pregnancy and fertility, urine chemistry, others. According to the research, the glucose monitoring segment had the largest share in the global poc diagnostics market. Based upon product, the global poc diagnostics market is categorized into hardware, software. In 2021, the hardware segment made up the largest share of revenue generated by the poc diagnostics market. On the basis of end user, the global poc diagnostics market has been segmented into hospitals and critical care centers, home care settings. Among these, the home care settings segment was accounted for the highest revenue generator in 2021. In terms of geography, the global poc diagnostics market has been segmented into Asia Pacific, Europe, North America, Rest of the World (RoW). North America captured the largest share of the market in 2021.

The global poc diagnostics market is highly competitive. Some of the leading companies operating in the market are Abaxis Inc., Abbott Laboratories, Becton Dickinson and Co., Chembio Diagnostics Inc., Danaher Corp., EKF Diagnostics Holdings plc, F. Hoffmann-La Roche AG, Koninklijke Philips N.V., OraSure Technologies Inc., Quidel Corporation, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Werfen GmbH, Wipro Limited. Competitive landscape gives a description of the competitive nature of the global poc diagnostics market and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the poc diagnostics market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Type: alcohol and drug abuse, blood gas electrolyte and metabolite (BGEM), cardiac markers, cholesterol, glucose monitoring, hemoglobin/hemostasis, infectious diseases, pregnancy and fertility, urine chemistry, others
Product: hardware, software
End user: hospitals and critical care centers, home care settings
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028
Company mentioned: Abaxis Inc., Abbott Laboratories, Becton Dickinson and Co., Chembio Diagnostics Inc., Danaher Corp., EKF Diagnostics Holdings plc, F. Hoffmann-La Roche AG, Koninklijke Philips N.V., OraSure Technologies Inc., Quidel Corporation, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Werfen GmbH, Wipro Limited

Key Benefits for Stakeholders

– Get a comprehensive picture of the global poc diagnostics market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Poc diagnostics market overview
Part 3. Market breakdown by type
– Alcohol and drug abuse
– Blood gas electrolyte and metabolite (BGEM)
– Cardiac markers
– Cholesterol
– Glucose monitoring
– Hemoglobin/hemostasis
– Infectious diseases
– Pregnancy and fertility
– Urine chemistry
– Others
Part 4. Market breakdown by product
– Hardware
– Software
Part 5. Market breakdown by end user
– Hospitals and critical care centers
– Home care settings
Part 6. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 7. Key companies
– Abaxis, Inc.
– Abbott Laboratories
– Becton, Dickinson, and Co.
– Chembio Diagnostics, Inc.
– Danaher Corp.
– EKF Diagnostics Holdings plc
– F. Hoffmann-La Roche AG
– Koninklijke Philips N.V.
– OraSure Technologies, Inc.
– Quidel Corporation
– Siemens Healthineers AG
– Thermo Fisher Scientific Inc.
– Werfen GmbH
– Wipro Limited
About StrategyHelix
Disclaimer